NEW YORK (360Dx) – The US Food and Drug Administration on Wednesday cleared Philip's digital pathology system for marketing in the US.

The FDA cleared the Philips IntelliSite Pathology Solution, a whole-slide imaging system that enables the review and interpretation of digital surgical pathology slides prepared from biopsied tissue, through its do novo review pathway, making it the first time that the agency has allowed the marketing of a WSI system for such purposes, the agency said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.